{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:20:02Z","timestamp":1792545602730,"version":"4.5.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018568","name":"Special Fund Project for Science and Technology Innovation Strategy of Guangdong Province","doi-asserted-by":"publisher","award":["STKJ2021060"],"award-info":[{"award-number":["STKJ2021060"]}],"id":[{"id":"10.13039\/501100018568","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011840","name":"Shantou University Medical College","doi-asserted-by":"publisher","award":["2023GP002"],"award-info":[{"award-number":["2023GP002"]}],"id":[{"id":"10.13039\/501100011840","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011840","name":"Shantou University Medical College","doi-asserted-by":"publisher","award":["2024GP003"],"award-info":[{"award-number":["2024GP003"]}],"id":[{"id":"10.13039\/501100011840","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.critrevonc.2026.105179","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T08:00:20Z","timestamp":1770278420000},"page":"105179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Resistance mechanisms and post-trastuzumab deruxtecan (T-DXd) strategies in HER2+ and HER2-low breast cancer: From biology to clinical practice"],"prefix":"10.1016","volume":"221","author":[{"given":"Xiaofen","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wende","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwu","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danxia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weichun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7418","key":"10.1016\/j.critrevonc.2026.105179_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"ANON","year":"2012","journal-title":"Nature"},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105179_bib2","article-title":"Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study","volume":"41","author":"Abelman","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105179_bib3","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-24-2771","article-title":"TOP1 mutations and cross-resistance to antibody-drug conjugates in patients with metastatic breast cancer","volume":"31","author":"Abelman","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105179_bib4","article-title":"Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar","volume":"5","author":"Agostinetto","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105179_bib5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","article-title":"Resistance mechanisms to immune checkpoint inhibitors: updated insights","volume":"24","author":"Alsaafeen","year":"2025","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105179_bib6","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1200\/JCO.2010.30.8213","article-title":"Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study","volume":"29","author":"Andersson","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"10390","key":"10.1016\/j.critrevonc.2026.105179_bib7","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105179_bib8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41416-020-01175-y","article-title":"Treatment strategies for breast cancer brain metastases","volume":"124","author":"Bailleux","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105179_bib9","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105179_bib10","doi-asserted-by":"crossref","unstructured":"Bardia, A., O'Sullivan, C.C., Mahtani, R.L., Blau, S., Abdulla, N.E., Ali, A., Bansal, R., Meyer, J.M., George, M.A., Han, H.S., Pluard, T.J., Papish, S.W., Jones, J.M., Rong, Y., Gao, G., Rugo, H.S., 2024. An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC). J. Clin. Oncol. 42(16_suppl), TPS1122-TPS1122.","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS1122"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105179_bib11","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/neuonc\/noae123","article-title":"Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases","volume":"26","author":"Bartsch","year":"2024","journal-title":"Neuro Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105179_bib12","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","article-title":"Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial","volume":"28","author":"Bartsch","year":"2022","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105179_bib13","doi-asserted-by":"crossref","first-page":"vii36","DOI":"10.1093\/annonc\/mdq421","article-title":"Treatment of HER2-overexpressing breast cancer","volume":"21","author":"Baselga","year":"2010","journal-title":"Ann. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2026.105179_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS1100","article-title":"Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced\/metastatic breast or non-small cell lung cancer (NSCLC): a phase Ib, multicenter, study","volume":"38","author":"Borghaei","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105179_bib15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41523-025-00735-w","article-title":"Temporal evolution of breast cancer brain metastases treatments and outcomes","volume":"11","author":"Bottosso","year":"2025","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105179_bib16","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105179_bib17","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/S1470-2045(23)00676-9","article-title":"Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer","volume":"25","author":"Browne","year":"2024","journal-title":"Lancet Oncol."},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2026.105179_bib18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.1053","article-title":"Antibody drug conjugates treatment response score (ADC TRS) for sequencing trastuzuamb deruxtecan (T-DXd) and sacituzumab govitecan (SG) in advanced breast cancer (aBC)","volume":"43","author":"Cani","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105179_bib19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdw544","article-title":"3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)","volume":"28","author":"Cardoso","year":"2017","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105179_bib20","doi-asserted-by":"crossref","first-page":"e957","DOI":"10.1093\/oncolo\/oyae055","article-title":"Optimal sequential strategies for antibody-drug conjugate in metastatic breast cancer: evaluating efficacy and cross-resistance","volume":"29","author":"Chen","year":"2024","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105179_bib21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cac2.12387","article-title":"Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions","volume":"43","author":"Chen","year":"2023","journal-title":"Cancer Commun. (London England)"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105179_bib22","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cort\u00e9s","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105179_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102324","article-title":"Targeting brain metastases in breast cancer","volume":"103","author":"Corti","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105179_bib24","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","volume":"18","author":"Di\u00e9ras","year":"2017","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105179_bib25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1021\/bc9002019","article-title":"Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies","volume":"21","author":"Ducry","year":"2010","journal-title":"Bioconjug. Chem."},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2026.105179_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.1014","article-title":"Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: a French multicentre retrospective study","volume":"41","author":"Frenel","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105179_bib27","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"7668","key":"10.1016\/j.critrevonc.2026.105179_bib28","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"issue":"12_Supplement","key":"10.1016\/j.critrevonc.2026.105179_bib29","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-P4-03-23","article-title":"Abstract P4-03-23: Preclinical investigation for the mechanisms of action of PARP inhibition in combination with trastuzumab deruxtecan (T-DXd) in triple negative breast cancer (TNBC)","volume":"31","author":"Gonzalez-Gonzalez","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105179_bib30","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-24-1513","article-title":"Trastuzumab deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer: analysis of the phase Ib DS8201-A-U105 study","volume":"30","author":"Hamilton","year":"2024","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105179_bib31","doi-asserted-by":"crossref","unstructured":"Hamilton, E., Shapiro, C.L., Petrylak, D., Boni, V., Martin, M., Conte, G.D., Cortes, J., Agarwal, L., Arkenau, H.-T., Tan, A.R., Debruyne, P., Minchom, A., Rutten, A., Valdes-Albini, F., Yu, E.Y., Augustine, B., D'Amelio, A., Jr., Barrios, D., Hurvitz, S.A., 2021. Abstract PD3-07: Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study. Cancer Res. 81(4_Supplement), PD3-07-PD03-PD07.","DOI":"10.1158\/1538-7445.SABCS20-PD3-07"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105179_bib32","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105179_bib33","doi-asserted-by":"crossref","unstructured":"Hu, D., Lyu, X., Li, Z., Ekambaram, P., Dongre, A., Freeman, T., Joy, M., Atkinson, J.M., Brown, D.D., Cai, Z., Carleton, N.M., Crentsil, H.E., Little, Jt, Kemp, F., Klei, L.R., Beecher, M., Sperinde, J., Huang, W., Joensuu, H., Srinivasan, A., Pogue-Geile, K.L., Wang, Y., Feng, H., Eli, L.D., Lalani, A.S., Zou, J., Tseng, G.C., Bruno, T.C., Lee, A.V., Oesterreich, S., Wolmark, N., Allegra, C.J., Jacobs, S.A., McAllister-Lucas, L.M., Lucas, P.C., 2025. p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2(+) breast cancer that limits trastuzumab deruxtecan efficacy. Nat. Cancer.","DOI":"10.1038\/s43018-025-00969-4"},{"issue":"9_Supplement","key":"10.1016\/j.critrevonc.2026.105179_bib34","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PS08-04","article-title":"Abstract PS08-04: Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)","volume":"84","author":"Huppert","year":"2024","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105179_bib35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41523-025-00748-5","article-title":"Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)","volume":"11","author":"Huppert","year":"2025","journal-title":"NPJ Breast Cancer"},{"issue":"10371","key":"10.1016\/j.critrevonc.2026.105179_bib36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet (London, England)"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105179_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15082017","article-title":"Antibody-drug conjugates: ushering in a new era of cancer therapy","volume":"15","author":"Hurwitz","year":"2023","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105179_bib38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10549-019-05173-4","article-title":"Loss of HER2 after HER2-targeted treatment","volume":"175","author":"Ignatov","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105179_bib39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/CE.S217848","article-title":"Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy","volume":"14","author":"Ishii","year":"2019","journal-title":"Core Evid."},{"issue":"6_Supplement","key":"10.1016\/j.critrevonc.2026.105179_bib40","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-1366","article-title":"Abstract 1366: Dual immune checkpoint inhibition enhances the anti-tumor activity of trastuzumab deruxtecan in preclinical models","volume":"84","author":"Jenkins","year":"2024","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105179_bib41","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.annonc.2023.08.003","article-title":"Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial","volume":"34","author":"Jhaveri","year":"2023","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105179_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030997","article-title":"PARP inhibitors and proteins interacting with SLX4","volume":"15","author":"Jordheim","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105179_bib43","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/2767-9764.CRC-24-0302","article-title":"The tumor immune microenvironment and therapeutic efficacy of trastuzumab deruxtecan in gastric cancer","volume":"5","author":"Koganemaru","year":"2025","journal-title":"Cancer Res Commun."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105179_bib44","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol."},{"issue":"36","key":"10.1016\/j.critrevonc.2026.105179_bib45","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1200\/JCO.23.00882","article-title":"Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: a multicenter, phase I\/II trial","volume":"41","author":"Krop","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105179_bib46","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13046-024-03143-3","article-title":"The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer","volume":"43","author":"Lee","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105179_bib47","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.semcancer.2019.08.012","article-title":"Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets","volume":"60","author":"Liang","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105179_bib48","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47-SIRP\u03b1 immune checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2026.105179_bib49","article-title":"Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial","volume":"383","author":"Ma","year":"2023","journal-title":"BMJ (Clin. Res. Ed.)"},{"key":"10.1016\/j.critrevonc.2026.105179_bib50","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1476-4598-13-105","article-title":"Targeting of erbB3 receptor to overcome resistance in cancer treatment","volume":"13","author":"Ma","year":"2014","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105179_bib51","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrc3216","article-title":"RB: mitotic implications of a tumour suppressor","volume":"12","author":"Manning","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105179_bib52","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2020.02.016","article-title":"Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond","volume":"72","author":"Marchi\u00f2","year":"2021","journal-title":"Semin Cancer Biol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105179_bib53","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","article-title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Martin","year":"2017","journal-title":"Lancet Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105179_bib54","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","article-title":"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group","volume":"23","author":"Marty","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105179_bib55","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13058-015-0648-2","article-title":"The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review","volume":"17","author":"Mendes","year":"2015","journal-title":"Breast Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105179_bib56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105179_bib57","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105179_bib58","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105179_bib59","doi-asserted-by":"crossref","first-page":"S359","DOI":"10.1016\/j.annonc.2024.08.291","article-title":"343MO Unraveling the mechanisms of action and resistance to trastuzumab deruxtecan (T-DXd): supplementary biomarker analyses from DAISY trial","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105179_bib60","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105179_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003171","article-title":"Role of Fc\u03b3 receptors in HER2-targeted breast cancer therapy","volume":"10","author":"Musolino","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105179_bib62","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2005.01.041","article-title":"Herceptin: mechanisms of action and resistance","volume":"232","author":"Nahta","year":"2006","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105179_bib63","doi-asserted-by":"crossref","first-page":"763","DOI":"10.21037\/tlcr-23-800","article-title":"Molecular and immune characterization of Chinese early-stage non-squamous non-small cell lung cancer: a multi-omics cohort study","volume":"13","author":"Peng","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105179_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104470","article-title":"The ideal strategies of antibody-drug conjugate sequential treatment in HER2-expressing metastatic breast cancer: a multi-center real-world study","volume":"81","author":"Peng","year":"2025","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105179_bib65","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/neuonc\/noac144","article-title":"Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial","volume":"25","author":"P\u00e9rez-Garc\u00eda","year":"2023","journal-title":"Neuro Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105179_bib66","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41416-024-02766-9","article-title":"Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer","volume":"131","author":"Poumeaud","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"9_Supplement","key":"10.1016\/j.critrevonc.2026.105179_bib67","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PS08-02","article-title":"Abstract PS08-02: efficacy of Sacituzumab-Govitecan (SG) post Trastuzumab-deruxtecan (T-DXd) and vice versa for HER2low advanced or metastatic breast cancer (MBC): a French multicentre retrospective study","volume":"84","author":"Poumeaud","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105179_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102284","article-title":"Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan","volume":"53","author":"Pourjamal","year":"2025","journal-title":"Transl. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105179_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105179_bib70","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.breast.2015.07.008","article-title":"Clinical implications of the intrinsic molecular subtypes of breast cancer","volume":"24","author":"Prat","year":"2015","journal-title":"Breast"},{"issue":"4_Supplement","key":"10.1016\/j.critrevonc.2026.105179_bib71","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS21-P2-13-18","article-title":"Abstract P2-13-18: Activity and tolerability of combination of trastuzumab deruxtecan with olaparib in preclinical HER2+ and HER2-low breast cancer models","volume":"82","author":"Proia","year":"2022","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105179_bib72","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1200\/JCO.21.02937","article-title":"Margetuximab versus trastuzumab in patients with previously treated HER2-positive advanced breast cancer (SOPHIA): final overall survival results from a randomized phase 3 trial","volume":"41","author":"Rugo","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.critrevonc.2026.105179_bib73","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u2265 2 HER2-directed regimens: phase III NALA trial","volume":"38","author":"Saura","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105179_bib74","article-title":"Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to trastuzumab and trastuzumab deruxtecan","volume":"2024","author":"Sheng","year":"2024","journal-title":"medRxiv"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105179_bib75","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2026.105179_bib76","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.1076","article-title":"Comparing clinical benefit of trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in a large cohort of HER2-negative metastatic breast cancer (MBC)","volume":"43","author":"Sledge","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105179_bib77","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ijbiomac.2017.10.113","article-title":"Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy","volume":"110","author":"Son","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105179_bib78","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"Swain","year":"2013","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105179_bib79","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105179_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105330","article-title":"Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer","volume":"10","author":"Tarantino","year":"2025","journal-title":"ESMO Open"},{"issue":"12_Supplement","key":"10.1016\/j.critrevonc.2026.105179_bib81","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-P1-08-08","article-title":"Abstract P1-08-08: Real-world efficacy of immediate subsequent lines of therapy after trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (MBC) \u2013 retrospective study from the nationwide Flatiron database","volume":"31","author":"Tarantino","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105179_bib82","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","article-title":"ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann. Oncol."},{"issue":"17_suppl","key":"10.1016\/j.critrevonc.2026.105179_bib83","volume":"43","author":"Tolaney","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2026.105179_bib84","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS1123","article-title":"ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd)","volume":"42","author":"Tripathy","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105179_bib85","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1038\/s41467-025-58266-8","article-title":"Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)","volume":"16","author":"Tsao","year":"2025","journal-title":"Nat. Commun."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105179_bib86","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105179_bib87","first-page":"221","article-title":"Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity","volume":"7","author":"Wang","year":"2024","journal-title":"Antib. Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105179_bib88","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.2008.21.6531","article-title":"Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer","volume":"28","author":"Wardley","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105179_bib89","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10549-022-06775-1","article-title":"Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study","volume":"197","author":"Xu","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105179_bib90","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1470-2045(20)30702-6","article-title":"Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Xu","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105179_bib91","doi-asserted-by":"crossref","DOI":"10.21037\/tbcr-20-25","article-title":"Pyrotinib plus capecitabine for human epidermal factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study","volume":"1","author":"Yan","year":"2020","journal-title":"Transl. Breast Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105179_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217900","article-title":"Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates","volume":"630","author":"Yazdi","year":"2025","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105179_bib93","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.annonc.2019.11.019","article-title":"The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers","volume":"31","author":"Yver","year":"2020","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105179_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111536","article-title":"Targeting FAK improves the tumor uptake of antibody-drug conjugates to strengthen the anti-cancer responses","volume":"28","author":"Zhang","year":"2025","journal-title":"iScience"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826000661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:21:40Z","timestamp":1777605700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826000661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":94,"alternative-id":["S1040842826000661"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105179","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistance mechanisms and post-trastuzumab deruxtecan (T-DXd) strategies in HER2+ and HER2-low breast cancer: From biology to clinical practice","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105179","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105179"}}